ArticleJournal of clinical medicine2019

Safety and Activity of Metronomic Temozolomide in Second-Line Treatment of Advanced Neuroendocrine Neoplasms.

Salvatore Tafuto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.